EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Vergleichsstudie

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial

Yu Sunakawa iD, Manabu Shiozawa, Takanori Watanabe, Hirofumi Ota iD, Hisateru Yasui iD, Taichi Yabuno iD, Mitsuyoshi Tei iD, Mitsugu Kochi, Dai Manaka iD, Hisatsugu Ohori, Tatsuro Yamaguchi iD, Tamotsu Sagawa und 8 weitere

Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3099-3104

DOI: 10.1200/jco-26-00355 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Yu Sunakawa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Cetuximab, Colorectal Neoplasms. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The randomized phase II DEEPER trial (jRCTs061180022) previously reported superior depth of response with modified 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (m-FOLFOXIRI) plus cetuximab versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer (mCRC). Here, we report updated final survival outcomes and exploratory subgroup analyses focusing on RAS / BRAF wild-type and left-sided tumors. Final overall survival (OS) and progression-free survival (PFS) were analyzed in the per-protocol set (PPS) with exploratory subgroup analyses according to the presence of liver-limited disease and sex, using extended follow-up data. There were no differences in PFS and OS in the PPS. In patients with RAS / BRAF wild-type and left-sided tumors, median PFS was longer with cetuximab than with bevacizumab (14.8 v 11.9 months; hazard ratio [HR], 0.71 [95% CI, 0.52 to 0.97]; P = .029). The median OS was 50.2 months for cetuximab and 40.2 months for bevacizumab (HR, 0.74 [95% CI, 0.53 to 1.05]). In the exploratory analyses, cetuximab-based therapy was associated with longer OS in male patients (HR, 0.59; P = .016) and in patients with extrahepatic disease (HR, 0.60; P = .014). In conclusion, the DEEPER trial suggests that m-FOLFOXIRI plus cetuximab achieves superior tumor shrinkage and may be associated with favorable outcomes in selected patients with RAS / BRAF wild-type and left-sided mCRC, with exploratory signals of benefit in male patients and those with extrahepatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCetuximabColorectal NeoplasmsProto-Oncogene Proteins B-rafAdultAgedFemaleHumansMaleMiddle AgedCamptothecinFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsProgression-Free Survival

Substanzen

BevacizumabBRAF protein, humanCamptothecinCetuximabFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Surgery, Tokushima Municipal Hospital, Tokushima, Japan.
  • Department of Gastroenterological Surgery, Ikeda City Hospital, Ikeda, Japan.
  • Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Gastroenterological Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.

ORCID-Profile: Yu Sunakawa, Hirofumi Ota, Hisateru Yasui, Taichi Yabuno, Mitsuyoshi Tei, Dai Manaka, Tatsuro Yamaguchi, Masahito Kotaka, Yutaro Kubota, Wataru Ichikawa, Akihito Tsuji

Zitieren

APA

Sunakawa, Y., Shiozawa, M., Watanabe, T., Ota, H., Yasui, H., Yabuno, T., Tei, M., Kochi, M., Manaka, D., Ohori, H., Yamaguchi, T., Sagawa, T., Kotaka, M., Kubota, Y., Sekikawa, T., Nakamura, M., Takeuchi, M., Ichikawa, W., Fujii, M., & Tsuji, A. (2026). Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial. Journal of Clinical Oncology, 44(32), 3099-3104. https://doi.org/10.1200/jco-26-00355

Vancouver

Sunakawa Y, Shiozawa M, Watanabe T, Ota H, Yasui H, Yabuno T, et al. Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial. Journal of Clinical Oncology. 2026;44(32):3099-3104. doi:10.1200/jco-26-00355

BibTeX
@article{Sunakawa2026,
  author = {Sunakawa, Yu and Shiozawa, Manabu and Watanabe, Takanori and Ota, Hirofumi and Yasui, Hisateru and Yabuno, Taichi and Tei, Mitsuyoshi and Kochi, Mitsugu and Manaka, Dai and Ohori, Hisatsugu and Yamaguchi, Tatsuro and Sagawa, Tamotsu and Kotaka, Masahito and Kubota, Yutaro and Sekikawa, Takashi and Nakamura, Masato and Takeuchi, Masahiro and Ichikawa, Wataru and Fujii, Masashi and Tsuji, Akihito},
  title = {Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {32},
  pages = {3099--3104},
  doi = {10.1200/jco-26-00355}
}
Kostenlos starten →